

Online supplementary table 3. Plasma concentrations of levosimendan metabolites OR-1855 and OR-1896 (by acetylation status) prior to the study treatment intake in the morning of day 14 of a crossover study period.

Acetylation status	Levosimendan daily dose		1 mg		1 mg bd	
	Analyte	OR-1855 (ng/ml)	OR-1896 (ng/ml)	OR-1855 (ng/ml)	OR-1896 (ng/ml)	OR-1896 (ng/ml)
Slow acetylators	N	16	16	15	15	
	Mean (SD)	1.82 (0.91)	1.10 (0.52)	3.72 (2.67)	2.24 (1.29)	
Slow (or intermediate) acetylators	N	14	14	11	11	
	Mean (SD)	1.69 (1.11)	1.21 (0.51)	4.59 (1.84)	2.60 (1.08)	
Intermediate (or rapid) acetylators	N	23	23	23	23	
	Mean (SD)	0.80 (0.47)	1.82 (0.94)	2.09 (1.16)	4.55 (1.97)	
Rapid acetylators	N	3	3	3	3	
	Mean (SD)	0.82 (0.26)	3.01 (0.32)	1.80 (0.66)	6.18 (0.47)	
Status unavailable	N	2	2	3	3	
	Mean (SD)	2.08 (1.70)	3.01 (1.05)	7.14 (4.82)	16.1 (4.20)	
All	N	58	58	55	55	
	Mean (SD)	1.34 (0.94)	1.58 (0.89)	3.30 (2.42)	4.25 (3.56)	